Literature DB >> 12972432

Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression.

Lidija Klampfer1, Jie Huang, Georgia Corner, John Mariadason, Diego Arango, Takehiko Sasazuki, Senji Shirasawa, Leonard Augenlicht.   

Abstract

Endogenous interferon gamma (IFNgamma) promotes the host response to primary tumors, and IFNgamma-insensitive tumors display increased tumorigenicity and can evade tumor surveillance mechanisms. Here we demonstrate that activating mutations of Ki-ras are sufficient to inhibit the expression of STAT1 and STAT2, transcription factors required for signaling by IFNs, providing a potential mechanism for the insensitivity of tumors to IFNs. We demonstrated that colon cancer cell lines with Ki-ras mutations display reduced expression of IFN-responsive genes compared with the cell lines that have retained wild type Ras and that inactivation of the mutant Ki-ras allele in the HCT116 colon cancer cell line is sufficient to restore the expression of STAT1, STAT2, and IRF-9. Accordingly, the expression of 27 interferon-inducible genes was reduced in HCT116 cells compared with the isogenic clones with targeted deletion of the mutant Ki-ras allele, Hkh2 and Hke-3. The expression of IFNgamma receptors did not differ among the isogenic cell lines. IFNgamma stimulated transcription of a STAT1-dependent reporter gene was impaired by RasV12, demonstrating a transmodulation of IFN/STAT signaling by activated Ras. Finally, we demonstrated that the expression of RasV12 in 293T cells is sufficient to inhibit the endogenous expression of STAT1 and STAT2, confirming the negative regulation of IFN signaling by oncogenic Ras. Our data demonstrate that the signaling initiated by activated Ki-ras interferes with the IFN/STAT signaling pathway and modulates the responsiveness of cancer cells to interferons. Furthermore, the data suggest that tumors harboring activating Ki-ras mutations may escape tumor surveillance mechanisms due to reduced responsiveness to IFNgamma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972432     DOI: 10.1074/jbc.M304721200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  The role of signal transducer and activator of transcription-2 in the interferon response.

Authors:  Håkan C Steen; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2012-01-26       Impact factor: 2.607

2.  Nogo to IFN by Ras.

Authors:  Maya Shmulevitz; Adil Mohamed
Journal:  Cell Cycle       Date:  2015-06-23       Impact factor: 4.534

3.  Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.

Authors:  Qi Zhang; Rui Gong; Jing Qu; Yijing Zhou; Weiyong Liu; Mingzhou Chen; Yingle Liu; Ying Zhu; Jianguo Wu
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

4.  KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.

Authors:  Wenting Liao; Michael J Overman; Adam T Boutin; Xiaoying Shang; Di Zhao; Prasenjit Dey; Jiexi Li; Guocan Wang; Zhengdao Lan; Jun Li; Ming Tang; Shan Jiang; Xingdi Ma; Peiwen Chen; Riham Katkhuda; Krittiya Korphaisarn; Deepavali Chakravarti; Andrew Chang; Denise J Spring; Qing Chang; Jianhua Zhang; Dipen M Maru; Dean Y Maeda; John A Zebala; Scott Kopetz; Y Alan Wang; Ronald A DePinho
Journal:  Cancer Cell       Date:  2019-03-21       Impact factor: 31.743

5.  Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway.

Authors:  Sarah M Battcock; Thaddeus W Collier; Dong Zu; Kensuke Hirasawa
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21.

Authors:  José M Escandell; Pawan Kaler; M Carmen Recio; Takehiko Sasazuki; Senji Shirasawa; Leonard Augenlicht; José-Luis Ríos; Lidija Klampfer
Journal:  Biochem Pharmacol       Date:  2008-05-08       Impact factor: 5.858

7.  Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression.

Authors:  Sanjay Chandrasekaran; Maiko Sasaki; Christopher D Scharer; Haydn T Kissick; Dillon G Patterson; Kelly R Magliocca; John T Seykora; Bishu Sapkota; David A Gutman; Lee A Cooper; Gregory B Lesinski; Edmund K Waller; Susan N Thomas; Sergei V Kotenko; Jeremy M Boss; Carlos S Moreno; Robert A Swerlick; Brian P Pollack
Journal:  Mol Cancer Res       Date:  2019-09-23       Impact factor: 5.852

8.  Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels.

Authors:  Sherri L Christian; Thaddeus W Collier; Dong Zu; Maria Licursi; Chris M Hough; Kensuke Hirasawa
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  Mouse gammaherpesvirus-68 infection acts as a rheostat to set the level of type I interferon signaling in primary macrophages.

Authors:  Brittani M Wood; Wadzanai P Mboko; Bryan C Mounce; Vera L Tarakanova
Journal:  Virology       Date:  2013-05-23       Impact factor: 3.616

10.  KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.

Authors:  Neeraj Lal; Brian S White; Ghaleb Goussous; Oliver Pickles; Mike J Mason; Andrew D Beggs; Philippe Taniere; Benjamin E Willcox; Justin Guinney; Gary W Middleton
Journal:  Clin Cancer Res       Date:  2017-10-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.